For BRAF-Mutated Colorectal Cancer, Encorafenib, Cetuximab, and Alpelisib May Be Effective

Share this content:

the Cancer Therapy Advisor take:

According to new preliminary findings presented at the 26th EORTC-NIC-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, researchers have found that a combination of cetuximab, an epidermal growth factor receptor (EGFR) inhibitor, encorafenib, a BRAF inhibitor, and alpelisib, a PI3K pathway inhibitor, may be an effective treatment for patients with BRAF-mutated advanced colorectal cancer.

For the phase 1 study, which is still continuing to enroll participants, patients with BRAF-mutated colorectal cancer were randomly assigned to receive encorafenib orally once daily plus cetuximab 250mg/m2 weekly (400mg/m2 initial loading dose) with or without alpelisib orally once daily.

Results showed that the two-drug combination shrank tumors in 23% of patients compared with 32% in the three-drug combination group. In addition, the median duration of progression-free survival was 16 weeks and 19 weeks for the two-drug and three-drug combination groups, respectively.

The researchers note that although the standard of care is not being compared in this study, the progression-free survival times observed in this study are nearly double those for patients who have been treated with standard therapy in the past. Furthermore, the combination of drugs was generally well-tolerated among patients.

For BRAF-Mutated Colorectal Cancer, Encorafenib, Cetuximab, and Alpelisib May Be Effective
Cetuximab, encorafenib, and alpelisib, may be an effective treatment.
Patients with a form of advanced colorectal cancer that is driven by a mutated version of the BRAF gene have limited treatment options available. However, results from a multi-centre clinical trial suggest that the cancer may respond to a combination of three targeted drugs.

Professor Josep Tabernero, head of the medical oncology department at Vall d'Hebron University Hospital and director of the Vall d'Hebron Institute of Oncology, Barcelona, Spain, will tell the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona today (Friday) that he and colleagues in a number of different countries are investigating a BRAF inhibitor, encorafenib, combined with cetuximab, which inhibits the epidermal growth factor receptor (EGFR), with or without a third drug, alpelisib, which inhibits another cancer-causing pathway called PI3K, in a phase I clinical trial for patients with advanced BRAF-mutated colorectal cancer.

READ FULL ARTICLE From Medical Express

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs